Oppenheimer reaffirmed their hold rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a report issued on Monday.

Several other analysts have also weighed in on the company. HC Wainwright restated a buy rating and issued a $62.00 price objective on shares of Acceleron Pharma in a report on Monday. Credit Suisse Group set a $51.00 price objective on Acceleron Pharma and gave the company a buy rating in a report on Tuesday, November 14th. Royal Bank of Canada restated a hold rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. ValuEngine lowered Acceleron Pharma from a hold rating to a sell rating in a report on Friday, October 6th. Finally, Barclays upped their price objective on Acceleron Pharma from $42.00 to $50.00 and gave the company an overweight rating in a report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Acceleron Pharma currently has a consensus rating of Buy and an average price target of $44.56.

Acceleron Pharma (XLRN) opened at $35.92 on Monday. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.55) earnings per share. research analysts predict that Acceleron Pharma will post -2.65 EPS for the current year.

In related news, SVP John D. Quisel sold 5,113 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $38.42, for a total transaction of $196,441.46. Following the transaction, the senior vice president now directly owns 57,918 shares of the company’s stock, valued at $2,225,209.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Corp /De/ Celgene purchased 745,592 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The shares were acquired at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the completion of the transaction, the insider now directly owns 6,118,479 shares of the company’s stock, valued at approximately $226,383,723. The disclosure for this purchase can be found here. 3.90% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new position in Acceleron Pharma during the third quarter valued at $1,496,000. Iguana Healthcare Management LLC acquired a new position in Acceleron Pharma during the third quarter valued at $2,612,000. Point72 Asset Management L.P. acquired a new position in Acceleron Pharma during the third quarter valued at $2,721,000. Granahan Investment Management Inc. MA raised its position in Acceleron Pharma by 15.2% during the third quarter. Granahan Investment Management Inc. MA now owns 217,091 shares of the biopharmaceutical company’s stock valued at $8,102,000 after buying an additional 28,694 shares during the period. Finally, Perceptive Advisors LLC raised its position in Acceleron Pharma by 127.2% during the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after buying an additional 905,000 shares during the period. 85.84% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/12/12/acceleron-pharmas-xlrn-hold-rating-reaffirmed-at-oppenheimer.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.